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Microstructural characterisation of normal and malignant human prostate 
tissue with VERDICT MRI 
 
Abstract  
 
Objectives Demonstrate the feasibility of the recently introduced VERDICT 
(Vascular, Extracellular and Restricted DIffusion for Cytometry in Tumours) 
framework for imaging prostate cancer with diffusion-weighted Magnetic Resonance 
Imaging (DW-MRI) within a clinical setting. 
 
Materials and Methods VERDICT is a non-invasive microstructure imaging 
technique that combines an in-depth diffusion MRI acquisition with a mathematical 
model to estimate and map microstructural tissue parameters such as cell size and 
density, and vascular perfusion. In total 8 patients underwent 3T MRI using 9 
different b values (100-3000 s/mm2).  All patients were imaged before undergoing 
biopsy. Experiments with VERDICT analysed DW-MRI data from patients with 
histologically confirmed prostate cancer in areas of cancerous and benign peripheral 
zone tissue. For comparison we also fitted commonly used diffusion models such as 
the Apparent Diffusion Coefficient (ADC), the Intravoxel Incoherent Motion (IVIM) 
and the Kurtosis model. We also investigated correlations of ADC and Kurtosis with 
VERDICT parameters to gain some biophysical insight into the various parameter 
values. 
Results 8 patients had prostate cancer in the peripheral zone with Gleason score 3+3 
(n=1), 3+4 (n=6) and 4+3 (n=1). The VERDICT model identified a significant 
increase in the intracellular and vascular volume fraction estimates in cancerous 
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compared to benign peripheral zone, as well as a significant decrease in the volume of 
the extracellular-extravascular space (EES) (P=0.05). This is in agreement with 
manual segmentation of the biopsies for prostate tissue component analysis, which 
found proliferation of epithelium, loss of surrounding stroma and an increase in 
vasculature. The standard ADC and Kurtosis parameters were also significantly 
different (P=0.05) between tissue types. There was no significant difference in any of 
the IVIM parameters (P=0.11 to 0.29). VERDICT parametric maps from voxel by 
voxel fitting clearly differentiated cancer from benign regions. ADC and Kurtosis 
parameters correlated most strongly with VERDICT’s intracellular volume fraction, 
but also moderately with the EES and vascular fractions. 
Conclusions VERDICT distinguished tumour from benign areas, while revealing 
differences in microstructure descriptors such as cellular, vascular and EES fractions. 
The parameters of ADC and Kurtosis models also discriminated between cancer and 
benign regions. However, VERDICT provides more specific information that 
disentangles the various microstructural features underlying the changes in ADC and 
Kurtosis.  These results highlight the clinical potential of the VERDICT framework 
and motivate the construction of a shorter, clinically viable, imaging protocol to 
enable larger trials leading to widespread translation of the method. 
Key words: VERDICT MRI, prostate cancer, cancer imaging, microstructure, 
compartment model.  
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Introduction 
 
Prostate cancer is the most common cancer among males in all economically 
developed countries (1). The standard procedure to provide a diagnosis of the disease 
is transrectal prostate biopsy, which is invasive with possible unpleasant side effects 
(2) and is prone to error (3). Imaging based diagnostic strategies, using techniques 
such as multi-parametric magnetic resonance imaging (MRI), show great promise (4) 
providing useful information on the location and the stage of disease. Diffusion-
weighted MRI (DW-MRI) is an integral component of the multi-parametric MRI 
examination, because of its unique sensitivity to the microscopic structure of the 
tissue. In particular, histological features such as the cellular density, cellular size and 
shape and cellular arrangement, all influence tissue-water mobility, so differences in 
these features produce image contrast in DW-MRI. These same microstructural 
characteristics, are evaluated by histopathologists to determine the Gleason grade of 
prostate cancers. Hence, DW-MRI offers great potential value as a non-invasive 
diagnostic probe for cancer pathology.  
Most DW-MRI studies have used the technique in its simplest form by calculating the 
apparent diffusion coefficient (ADC) to identify clinically significant tumour foci 
more clearly (5, 6). In general, ADC values are lower in prostate carcinoma compared 
to healthy tissue and are believed to reflect the highly cellular environment of 
neoplastic tissue, which constrains water mobility. However, this simplified model of 
water diffusion remains a blunt tool, which fails to discriminate the variety of 
histological changes (cell density, size, shape, permeability, subcellular architecture, 
and vascular perfusion effects) that occur within cancers. Indeed, the overall 
sensitivity of ADC as a quantitative determinant of the presence or absence of tumour 
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within a given region remains limited, as ADC values in prostatic cancer and in 
benign prostatic tissue vary widely and overlap substantially (7-9). Biophysical 
mechanisms affect ADC in different ways that can even compete and cancel each 
other. Furthermore, the simultaneous dependence of ADC on a variety of histological 
features simultaneously means that it lacks biological specificity; a factor which likely 
limits its ability to distinguish cancer from other common pathologies, such as 
prostatitis and hyperplasia.  
A variety of more sophisticated DW-MRI models have recently been reported to 
improve sensitivity and specificity for cancer diagnosis.  
Diffusion kurtosis imaging (DKI) is a generalisation of ADC estimation (10) that 
quantifies the Gaussian and non-Gaussian components of the diffusion behaviour in 
tissue. Several studies have demonstrated greater discriminatory sensitivity of DKI for 
benign and prostate cancer tissue than standard ADC (11, 12). Yet, as for ADC, DKI 
lacks specificity to the underlying microstructural features that cause the changes 
(13).  
Le Bihan et al (14)  proposed the intravoxel incoherent motion (IVIM) model to 
separate “pure” water diffusion effects in the tissue from pseudo-diffusion of water in 
the blood capillary network. IVIM characterises water dispersion as a combination of 
a slow component associated with Brownian motion and a fast component associated 
with the bulk motion of molecules inside microcapillaries (14, 15). IVIM has been 
used to study various cancer types such as breast (16), prostate (9) and pancreatic (17, 
18) tumours, showing improvement in data description compared to ADC. However, 
its description of diffusion in the cellular component of the tissue remains simplistic: 
it does not account for cellular geometry and compartmentalisation.  This has led to 
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sometimes poor reproducibility and unreliable estimates of both fast and slow 
diffusion parameters from the DW-MRI signal (9, 19-22).  
The recent VERDICT framework (23) uses a three compartment tissue model 
designed to capture the main histological features that influence the DWI signal from 
in-vivo cancer tumours. The three compartments account explicitly for i) water 
trapped in cells, ii) water in the vascular network, and iii) interstitial water. Thus, in 
contrast to ADC, Kurtosis and IVIM models, VERDICT provides estimates of 
specific tissue properties such as the size and packing density of the cells, the vascular 
and extracellular-extravascular space (EES) volume fractions. The original 
presentation of VERDICT demonstrated its use in tumour xenograft models of 
colorectal cancer (23). Experiments identified and quantified i) known differences in 
the microstructure of two human colorectal tumours (LS174T and SW1222) with 
differing cellular and vascular phenotypes; and ii) a significant decrease in cell size 
following administration of a chemotherapeutic agent indicating Apoptotic Volume 
Decrease. In contrast the standard ADC and IVIM models failed to identify either 
difference. These results show promise for the potential of the VERDICT framework 
for non-invasive histology and motivate translation to clinical practice for providing 
sensitive biomarkers of tumour type without the need for biopsy. 
This feasibility study assesses the ability of the VERDICT model to differentiate 
between benign and cancerous prostate tissue in a clinical setting, while comparing its 
performance with more established models (ADC, Kurtosis, IVIM). The cellular and 
vascular architecture of the normal prostatic tissue changes dramatically with disease.  
Notably in prostate carcinoma there is profound increase of glandular elements, which 
coincides with the proliferation of epithelial cells as well as capillary 
	   6	  
neovascularization (13, 24). VERDICT is designed to reflect these changes as the 
intracellular and vascular volume fractions are influenced by the signal from these 
cellular and vascular structures (Figure 1). To test its potential, we acquired uniquely 
rich DW-MRI data sets with a wide range of diffusion times and diffusion weightings 
from a small set of prostate-cancer patients. This data set demonstrates the feasibility 
of VERDICT for providing non-invasive measurements of histological parameters in 
a clinical setting and motivates the construction of more economical protocols for 
widespread application of VERDICT in the clinic.  
Materials and Methods 
 
Patient population This study was performed with informed patient consent and 
local ethics committee approval. The standard of reference was histology following 
transperineal template mapping (TPM) biopsy (25). TPM biopsies systematically 
sample the whole prostate and therefore provide high accuracy for the detection of 
clinically significant prostate cancer tumours. Between October 2012 and July 2013, 8 
patients with elevated PSA levels consented to have multiple b value DW-MRI as 
described below. The inclusion criteria for the patients of this study for VERDICT 
analysis were (i) no prior hormonal or radiation treatment and (ii) a region of cancer 
on MRI in the peripheral zone (PZ), with histologically positive results for cancer in 
the corresponding region confirmed after the MRI scan. All 8 patients met our 
inclusion criteria for VERDICT analysis and were pristine patients 
  
MRI acquisition 
We imaged 8 patients (prior to TPM biopsy) on a Philips Achieva 3T MRI 
scanner using conventional multi-parametric MRI (26, 27) supplemented by 
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additional DW-MRI sequences specifically for VERDICT modelling. Imaging used a 
32 channel cardiac coil with the patient in the supine position.  For anatomical 
imaging, the entire prostate gland was imaged with a T2-weighted acquisition (echo 
time (TE)= 100ms, repetition time (TR)= 5407ms, flip angle 90°, matrix 448×448, 
field of view (FOV) = 180x180mm2, 3mm slice thickness, 30 slices). DW-MRI was 
performed in the axial plane using a pulse gradient spin echo (PGSE) sequence, with 
data acquired using single-shot echo planar imaging (EPI). Three orthogonal 
directions were used for each of the 9 b values (100, 200, 400, 800, 1000, 1500, 2000, 
2500, 3000 s/mm2). The DW-MRI sequence was acquired with a voxel size of 
1.3×1.3×5mm3, 5mm slice thickness, 14 slices and FOV=220×220mm2, and images 
were reconstructed to a 176×176 matrix size. More parameters are detailed in Table 1. 
The data was normalised to avoid T2 dependence with a b=0 image for every echo 
time (TE). The total duration of the scan for each patient was approximately 35 
minutes, which is at the limit of what the patients would tolerate. As such this 
provides the richest possible data for assessing the potential benefits of VERDICT 
MRI.  
 
Image Analysis 
Based on multi-parametric MRI findings, an experienced radiologist  (S.P., with 9 
years of experience in prostate MR imaging;) contoured the focal areas 
most suspicious for tumour within the PZ of the prostate. The MRI suspicious regions 
of interest (ROI) were subsequently targeted and confirmed as cancer by TPM biopsy. 
The ROIs were chosen to be as large as possible, while having minimal contamination 
from unintended tissues. For the purposes of image interpretation the tumour ROIs 
were defined as a focal area that displayed i) local low signal intensity on T2-
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weighted images and/or ii) high intensity on a DW image with high b value (Figure 
2).  All 8 patients with PZ identified suspicious MRI findings had histologically-
confirmed tumour on targeted biopsy cores. Following review of the biopsy result to 
confirm the absence of tumour on the contralateral side of the PZ, the same 
radiologist located an ROI for each patient in an area of benign PZ.  
 
Data Processing 
We fit the ADC, Kurtosis, IVIM and VERDICT models to the data using a similar 
iterative optimization procedure to (23, 28) that accounts for local minima and Rician 
noise. The experiments first fit the models to data averaged over all voxels within 
tumour and benign regions and subsequently in each voxel. The signal to noise ratio 
(SNR) was calculated using the method described in (29) that accounts for the 
spatially variant noise in the DW-MR images. The median SNR, at b=0, for our 
patient data sets was 14. 
 
Mathematical models 
The ADC model is a simple monoexponential description of the signal decay as a 
function of b; it assumes an isotropic Gaussian distribution of water-molecule 
displacements and has one parameter, the ADC d. The normalised signal is 
 𝑆 = exp −𝑏𝑑 . 1 
 
The diffusion Kurtosis model generalises the ADC model to relax the assumption of 
Gaussian water dispersion. It has two parameters K, and Dk. The diffusivity parameter 
Dk is similar to the ADC parameter, while the kurtosis parameter K quantifies the 
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deviation of the dispersion pattern from a Gaussian distribution. The normalised 
signal under the Kurtosis model is 
 𝑆 =   exp −𝑏𝐷! + 16 𝑏!𝐷!!𝐾 . 2 
 
The IVIM model is biexponential assuming ADC models for each of two non-
exchanging pools of water molecules, one vascular and one cellular. The parameters 
of the model are ffast fslow, Dfast, and Dslow, where ffast, Dfast and fslow, Dslow are the 
volume fraction and the diffusion coefficient associated with the fast (vascular) and 
the slow (cellular) compartments, respectively, with ffast + fslow = 1. The normalised 
signal is 
 𝑆 =   𝑓!"#$  exp  (−𝑏𝐷!"#$  )+ 𝑓!"#$  exp  (−𝑏𝐷!"#$  ). 3 
 
VERDICT is a three-compartment model that characterises water diffusion in 
the vascular, extracellular-extravascular space (EES) and intracellular (IC) 
compartments in tumours. Mathematically, VERDICT is the sum of three parametric 
models, each describing the diffusion MR signal in a separate population of water 
from one of the three components. The model assumes no exchange between the three 
water populations. The normalised signal for the VERDICT model is  
 𝑆 =    𝑓!!!!! 𝑆! 4 
where 𝑓!   is the proportion of signal with no diffusion weighting (b=0) from water 
molecules in population 𝑖, 0 ≤ 𝑓!   ≤ 1, 𝑓!!!!! = 1.  
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As specified in (22), the precise forms of the model components are application 
dependent. For prostate tissue, we use restricted diffusion in impermeable spheres 
(30) to model the signal for the IC compartment. This compartment has fIC 
(IC volume fraction), dIC, (IC diffusivity) and cell radius R as parameters. The model 
for the EES compartment uses an isotropic diffusion tensor (DT) model (31), so it has 
fEES (EES volume fraction) and dEES (diffusivity EES) as parameters. The vascular 
model assumes isotropically restricted water in cylinders with uniformly 
distributed orientations and zero diameter (AstroSticks in the terminology of (28)) and 
has fVASC (vascular volume fraction) and P (pseudo-diffusivity) as parameters. A 
schematic representation of the VERDICT model for prostate tissue is in Figure 1.  
In total we estimated 3 independent parameters for this study: fIC, fEES, and R. 
The other volume fraction fVASC= (1- fIC -fEES), and the diffusion and pseudo-diffusion 
coefficients were fixed to values that minimise fitting error averaged over all PZ 
voxels using data sets that were not included in the VERDICT analysis: dIC = dEES = 
2×10-9m2/s, P = 8×10-9m2/s. This particular form of VERDICT resulted from 
preliminary work on model selection, similar to (28, 32, 33), to identify a 
parsimonious model with the minimum number of parameters required to fit the data 
robustly. 
Histopathology 
For each patient after the prostate biopsy procedure the tissue samples were collected 
and placed in a paraffin block.  After paraffin embedding, microsections were placed 
on glass slides and stained with hematoxylin and eosin (H&E). Also 
immunohistochemical staining was performed for blood vessels and capillaries using 
the CD31 (PECAM-1, Leica Biosystems, Newcastle-upon-Tyne, UK) marker as per 
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standard methods. The cores were approximately 4µm thick and 1cm in length. Each 
lesion was measured in size and assigned a Gleason score by a histopathologist with 
10 years experience in genitourinary pathology.  A second histopathologist with 10 
years of experience verified the Gleason score findings. The histopathologist also evaluated	  the	  cellularity	  and	  vascularity	  of	  the	  samples. To quantify the prostate 
tissue components we performed manual segmentation of the core biopsies. For this 
histopathological analysis we considered all cancers (irrespective of Gleason grade) 
versus benign tissue.  
 
Statistical Analysis Each	  parameter	  of	  each	  model	  was	  evaluated	  for	  performance	  in	  differentiation 
between benign and cancerous tissue via a Wilcoxon matched pairs statistics. To 
perform statistical analysis we used the OriginPro 9.1 statistics software for Windows. 
We used nonparametric tests to assess differences between the paired malignant 
versus normal appearing PZ values. A P < 0.05 was taken to indicate significance in 
all methods. 
 
Results 
 
The 8 patients had histologically confirmed Gleason scores of 3+3 [n=1], 3+4 [n=6], 
4+3 [n=1] cancer in the PZ based on targeted biopsy cores. Patients with 3+3 score 
had cancer core length (CCL) of 3mm, with 3+4 had median CCL 7.5mm [range 5 to 
14mm] and with 4+3 had CCL 1mm. A summary of characteristics for the 8 patients 
is presented in Table 2. Histological analysis of the patient biopsies revealed 
prominent neovascularisation in cancer regions (one example shown in Figure 3A, B) 
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(vessels stain brown and are indicated with arrows) and found increased number of 
epithelial cells with evident reduction of the supporting stroma. To quantify the 
prostate tissue components we performed manual segmentation of the core biopsies 
labelling areas of blood vessels, lumen, epithelium and stroma. Figure 3C quantifies 
the increase in vasculature in tumour regions (162%) compared to benign. Figure 3D 
presents ratios for lumen, epithelial cells and stroma. The cancer shows increased 
proportions of lumen space (44%) and epithelium (470%), and reduction of stroma (-
62%).  
Figure 4 presents the fit of the VERDICT, ADC, IVIM and Kurtosis models to the 
data from a representative patient (63y, Gleason score 3+4), with the corresponding 
mean squared errors (MSE), by comparing the measured and predicted normalised 
diffusion signal S as a function of the diffusion weighting factor (b value). The 
VERDICT model captures the trends in the data for both benign and cancer ROIs 
with lower MSE than the ADC and IVIM models. The standard ADC and IVIM 
models exhibit clear departures: the ADC model signal prediction starts too high and 
ends up too low demonstrating that the signal decay is not monoexponential. The 
IVIM fails to estimate the signal at high b values in the cancer ROI, indicating that 
both models are unable to capture all the variation in the signal from both the cancer 
and benign tissue regions. The Kurtosis model fits both benign and cancer signals 
closely over their whole range in a similar way to VERDICT. Figure 5 compares 
more closely, over all patients, the VERDICT and Kurtosis models’ ability to explain 
the data averaged over the benign and cancer regions using Akaike’s Information 
Criterion (AIC) (34). AIC allows model comparison that accounts for differences in 
complexity (Kurtosis has 2 free parameters, while VERDICT has 3); the preferred 
model is the one with the minimum AIC score. In benign regions, the two models 
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have similar residual error score, so the AIC has a slight but consistent preference for 
the Kurtosis model, because of its simplicity. However, in cancer areas VERDICT 
shows consistent and often substantially smaller AIC than the Kurtosis model, 
indicating that the extra complexity of the model is needed to explain the data.  
Figure 6 compares parameter estimates from the ADC, IVIM, and VERDICT models 
from all patients fit to signals averaged over the benign and cancer ROIs. The d, Dk, K 
estimates are all significantly different (P =0.05) between tissue types with d, Dk 
lower and K higher in cancer than normal appearing tissue. None of the IVIM 
parameter estimates show significant differences between the tissue types (P =0.11 to 
0.29). The VERDICT volume fraction estimates for the IC, EES and vascular 
compartments are all significantly different between the benign and cancer tissue (P 
=0.05); note, however, that the three volume fractions are interdependent as they are 
constrained to sum to one. The IC and vascular volume fractions are higher while the 
EES fraction is lower in tumour than benign regions. There is no significant change in 
the cell radius estimate.  
Figure 7 illustrates parametric maps for an example patient (62y) with Gleason score 
3+4 tumour on the PZ for the ADC, Kurtosis and VERDICT models. These models 
showed significant differences in the averaged data over the ROIs of cancer versus 
benign tissue. The ADC map displays lower values for the tumour area as well as the 
Kurtosis Dk map. The Kurtosis K is higher for the tumour region as in the whole ROI 
analysis. Spatial mapping reveals clear differences in VERDICT parameters between 
the benign and cancer areas, particularly in the IC volume fraction, the EES volume 
fraction, and the radius index. The differences in those parameters between cancer 
and benign areas are broadly consistent with the whole-ROI VERDICT analysis. The 
cellularity map is an estimate of cell density obtained by dividing the intracellular 
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volume fraction estimate by the cube of the cell-radius (cell volume) estimate. It 
strongly highlights the tumour area by suppressing high values elsewhere in the 
prostate that other parameter maps show, unlike the ADC and Kurtosis maps. The 
microstructural maps also show heterogeneity within the tumour region, which may 
provide additional useful diagnostic information.  
Figure 8 investigates the relationship between the VERDICT and the ADC and 
Kurtosis parameters. It presents scatter plots for the tumour region of all the patients 
for voxel by voxel fitted values of d, Dk, K and fIC, R, fEES, fVASC. The colour coding 
distinguishes individual patients. We observe similar correlative trends for d and Dk: 
strong negative correlation with fIC, and moderate positive correlations with fEES and 
fVASC. The kurtosis K shows strong positive correlation with fIC and moderate negative 
correlation with fEES.  
Discussion  
Biomarkers sensitive to the pathophysiology of tumours are essential in the clinic for 
diagnosis and risk stratification (based on cancer grade and volume). Most current 
biomarkers come from histology, but the procedure is invasive, often challenging to 
perform, and limited to small sampling areas so are prone to errors. ADC derived 
from DW-MRI is increasingly used in cancer imaging to aid diagnosis, but is limited 
by the lack of specificity to individual histological features. The incorporation of an 
appropriate mathematical model is necessary to address this weakness and to develop 
DW-MRI as a source of non-invasive biomarkers of tumour histopathology, thereby 
improving patient classification, and perhaps ultimately limiting the requirement for 
biopsy. Previous studies using DW-MRI in prostate cancer have also assessed IVIM 
and Kurtosis techniques, however these models also lack specificity to the underlying 
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microstructure with significant overlap of parameter values between benign and 
cancerous tissue (11, 19, 21). VERDICT has the potential to overcome limitations of 
these simple models as it provides an effective probe of specific microstructural 
changes.  
In the present study we examined patients with biopsy proven prostate PZ cancer 
using VERDICT MRI.  Lesion-to-lesion comparisons with the patients’ tissue 
samples (Figure 3A-D) demonstrate how the volume fractions of different prostate 
tissue components vary over cancer and benign tissue. The main trends are a 
substantial increase in the proportion of epithelial tissue with prostate cancer while 
the volume of supporting stroma reduces.  This suggests that the high values of the 
VERDICT intracellular volume fraction and cellularity reflect the proliferation of 
epithelial cells in tumours, which contain densely packed cells with little extracellular 
space.  Also, the vascular staining in tumour areas showed the appearance of many 
new small blood vessels in close proximity to the tumour (neovascularisation). In 
contrast, areas of benign tissue had fewer large pre-existing vessels. These 
observations agree with the significant increase of the VERDICT vascular volume 
fraction and support the assignment of the prostate tissue compartments to the 
VERDICT model components illustrated in Figure 1. The observed VERDICT trends 
of increased cellularity and vasculature in cancerous versus normal prostate tissue are 
also well known and documented in the literature (13, 35).  
We found the VERDICT volume fraction estimates of the IC and vascular tissue 
components significantly higher for cancer than benign tissue (Wilcoxon test P=0.05). 
These results are in agreement with histological assessment of increased cellularity 
and vascularity within our patient cohort and with existing knowledge of prostate 
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cancer (13, 35).  Also the EES volume fraction was significantly lower for the tumour 
ROI than the benign region.  This reflects the sensitivity of the volume fraction 
parameters of VERDICT to discern microstructure previously seen in a preclinical 
study, where all of the volume fraction parameters showed significant differences 
between two tumour xenograft models of colorectal cancer with different cellular and 
vascular phenotypes (23). The	  parameter	  estimations	  in	  the	  current	  study	  were	  based	  on	  regions	  known	  to	  be	  cancerous	  or	  benign.	  To	  evaluate	  the	  ability	  of	  VERDICT	  to	  detect	  cancerous	  tissue,	  a	  more	  extensive	  blinded	  study	  is	  required. 
From the standard models d, Dk and K parameters were also significantly different (P 
=0.05) between tissue types, but none of the IVIM parameters (P =0.11to 0.29).  
Likewise both the IVIM and the ADC models were unable to describe the full range 
of the signal from the prostate data as shown in Figure 4, in contrast with VERDICT 
and the Kurtosis models.  Recent findings in Jambor et al (36), also concluded that the 
kurtosis model is better than the biexponential model for both normal and cancerous 
prostate tissue, but did not evaluate the VERDICT model. They found that the 
biexponential model fitted the data best, but with poor reproducibility, and hence, 
they preferred the kurtosis model overall. In our study we found that the kurtosis and 
VERDICT fitted the data more closely than the biexponential IVIM. As	  commonly	  used	  in	  the	  literature,	  we	  used	  unconstrained	  fits	  for	  the	  IVIM	  model	  and	  a	  wide	  range	  of	  b	  values.	  However,	  in	  comparing	  with	  VERDICT,	  the	  choice	  of	  b	  values	  may	  not	  have	  been	  optimal	  for	  IVIM	  parameter	  estimation. The differences in the 
fit of the biexponential model are most likely due to the different set of b values in the 
acquisition protocol. The biexponential model has also been shown elsewhere in 
literature to have a variable performance (20, 23, 37).    
The parametric maps from voxel by voxel fitting in Figure 7 reflect the trends seen in 
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the whole-ROI fitting in Figure 4. They showed elevated values of IC volume fraction 
in the tumour area and reduction of EES volume fraction. Furthermore combining the 
volume fraction of the IC component with the cell radius index allowed us to 
compose a cellularity map that clearly indicated only the tumour area as highly 
cellular and not other benign regions highlighted in the ADC d, and the kurtosis Dk, K 
parametric maps. The cellularity feature of the VERDICT model may have potential 
for improving the diagnostic procedure by eliminating deceptive false positives.  
Although both the ADC and Kurtosis models also revealed significant differences 
between the benign and tumour areas, a key advantage of VERDICT is that it assigns 
the differences to specific biophysical or histological factors. Comparison of ADC 
and Kurtosis parameters with VERDICT parameters provides some insight into the 
biophysical properties that affect the unspecific parameters, which may help interpret 
other studies that focus on ADC or Kurtosis parameters (5, 9, 36, 38). The scatter 
plots in Figure 8 showed strong negative correlation of the IC volume fraction with 
ADC d and Dk as well as moderate positive correlations with the EES and vascular 
volume fractions. These observations make sense, as we would expect ADC to 
decrease as the proportion of water trapped in cells increases and to increase as the 
proportion of water moving more rapidly in the vascular network increases. The 
kurtosis K exhibited opposite trends having positive correlation with the IC volume 
fraction and moderate negative correlation with the EES volume fraction. This again 
makes sense, as we would expect greater departures from Gaussian dispersion as the 
proportion of water restricted within cells increases. Although more data is necessary 
to establish better the relationship between the different parameters, the results do 
suggest that ADC and kurtosis confound various interesting histological effects, 
which further motivates the use of VERDICT parameters instead.  
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This study is an essential first step in the translation of the VERDICT technique to 
clinical practice. We have purposefully used an extended imaging protocol (compared 
to standard clinical imaging protocols) to obtain a uniquely rich data set with which to 
establish the best form for the VERDICT model and demonstrate its potential 
advantages. This limited the cohort size to 8 patients, which supports a comparison 
only of cancerous tissue against benign rather than a finer grained study of the 
contrast between different Gleason grades. Larger patient populations, with a wide 
range of tumour grades, are needed to evaluate the diagnostic benefit of VERDICT 
prior to clinical adoption. The results we present here are sufficiently compelling to 
motivate such a study.  Nonetheless, it requires a shorter acquisition protocol of 
approximately 10-15 minutes that is more feasible within the standard clinical 
workflow allowing it to supplement multi-parametric MRI examination. Thus the next 
step is to design a clinical acquisition protocol using, for example, the experiment 
design optimization in (39). Such optimization reduces scan time by producing the 
minimum optimal combination of b values for estimating the VERDICT parameters. 
The form of the model we have identified here with the rich data set is essential to 
underpin that process and the positive results motivate continuation to the next steps.  
Also the small cohort of our study consisted only of pristine patients.  Patients who 
have already undergone biopsies could potentially be analysed using VERDICT. 
Although previous studies have shown that diffusion MRI tends to be quite robust to 
the changes caused by biopsy, for example in active surveillance patients (40), it is 
possible that the new model may be more sensitive than standard DWI to the 
associated tissue disruption. Further work is required to investigate non-pristine 
patients. 
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In the future, the VERDICT model can be refined in a number of ways to incorporate 
more physiological parameters. However, as discussed in Panagiotaki et al (23), we 
believe that the current form of the model is as complex as the PGSE sequence on 
current clinical MRI scanners can support.  A range of other DW measurements could 
potentially allow incorporation of additional microstructural parameters in the model.  
For example, oscillating gradient DW-MRI could give access to subcellular structures 
such as the nuclei (38, 41, 42), while double pulsed-field gradient waveform 
sequences could inform about the shape (43) and permeability of cells (44). 
 
Conclusion 
In summary, we have demonstrated the utility of the VERDICT framework in a 
clinical setting for imaging prostate cancer. VERDICT successfully differentiated 
between benign and cancer regions while providing useful microstructural parameter 
estimates such as cell size, cellular, vascular and EES volume fractions. ADC d, Dk 
and K were also significantly different between types, unlike the IVIM parameters. 
The specificity of VERDICT analysis sheds light on the factors that affect and control 
the contrast in currently used methods such as ADC and DKI that have less direct 
biophysical foundation. Furthermore, the direct microstructural inferences could 
improve diagnosis and patient risk stratification, and help reduce the large number of 
false positive and false negative biopsies that currently arise from the Prostate 
Specific Antigen followed by the transrectal biopsy diagnostic pathway. Specifically, 
a promising advantage of this approach over simple ADC and DKI is the potential to 
eliminate the need for DCE-MRI, which is particularly pertinent to patients who 
cannot receive intravenous gadolinium-based contrast media. Most importantly, this 
feasibility study is a first step motivating the formation of a clinically viable imaging 
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protocol. This will allow large-scale evaluation of this technique to potentially offer 
and establish new non-invasive biomarkers for cancer diagnosis. 
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Tables  
 
Table 1 DW- MRI acquisition parameters, where DELTA is the time separation 
between the two pulses, delta is the duration of the pulses and |G| is the gradient 
strength. 
b value 
s/mm2 
DELTA/ delta 
ms 
TE ms TR 
ms 
|G| T/m 
 1000 26.6 / 8.5 55 2000 0.090181 
2000 29.4 / 11.3 60 2305 0.092374 
3000 31.6 / 13.5 65 2731 0.0921 
2500 30.7 / 12.6 63 2517 0.091095 
1500 28.1 / 10.0 58 2033 0.091966 
800 25.7 / 7.6 53 2000 0.091373 
400 23.7 / 5.6 49 2000 0.090323 
200 22.2 / 4.1 46 2000 0.089303 
100 21.2 / 3.1 44 2000 0.084886 
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Table 2 Characteristics of the 8 patients with confirmed prostate cancer 
 Mean Range 
Age (years)  65 55-82 
Prostate-specific antigen 
level (ng/ml) 
7.025 2-14.5 
Pathologic stage 
T2 5 
T3a 3 
Gleason Score 
3+3 1 
3+4 6 
4+3 1 
 
Figure Legends 
 
Figure 1 Schematic representation of the prostate tissue and the corresponding 
VERDICT model. The colour indicates the potential assignment of the tissue 
compartments to the model components (see Discussion). 
Figure 2 Gleason score 3+4 tumour on the PZ of a 74-year-old patient is seen as a 
focus of high signal intensity on a DW image of b value=3000s/mm2 (A). The tumour 
area is noted in magenta and the benign region in green. In (B) the tumour is seen as a 
homogenous focus of low signal intensity on the closest corresponding transverse T2-
weighted MR image. 
	   28	  
	  
Figure 3 Histological analysis and prostate tissue component ratios from manual 
segmentation of biopsy cores. A) Immunohistochemical detection of vasculature in 
benign tissue shows a small number of large blood vessels. B) In cancerous tissue 
staining reveals numerous new small capillaries near the glands. Blood vessels are 
outlined in brown and presented by arrows. Note the evident proliferation of epithelial 
cells and loss of surrounding stroma in cancer. Manual segmentation ratios of 
VERDICT patients’ biopsies for C) vasculature, D) lumen, epithelial cells and stroma.  
Figure 4 Fits of the VERDICT, ADC, IVIM and Kurtosis models to the data for an 
example data set of a 63-year-old patient with Gleason score 3+4. The symbols 
represent the measured data and the lines show the corresponding fits by the model. 
The normalized signal S is plotted as a function of the b value for all diffusion 
directions. The VERDICT and Kurtosis models provide a good fit, whilst the ADC 
and IVIM models fail to represent the whole range of the data. 
Figure 5 AIC scatter plots for the VERDICT and the kurtosis model with data from 
all the patients for signal averaged over the benign and cancer regions. Lower AIC 
scores indicate the best model. VERDICT consistently scores lower AIC for all 
cancer regions, while for benign areas the kurtosis model performs best.	  
Figure 6 Parameter estimates for all patients for the benign and cancer ROIs for (A) 
ADC, (B) IVIM, (C) VERDICT and (D) Kurtosis. Boxes define the interquartile 
range, whiskers the full range, the central lines the median and the dot the mean. 
Significant differences between groups are represented by asterisks (Wilcoxon test 
P<0.05). VERDICT volume fractions of the IC, EES and vascular compartments, and 
the ADC and Kurtosis parameters showed significant differences between the groups 
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of benign and cancer tissue. 
Figure 7 Parameter maps from 62-year-old patient with Gleason score 3+4 tumour on 
the PZ. In red we outline the tumour ROI and in black a benign region. A) Transverse 
T2 weighted image, B) ADC map, C) volume fraction map of the intracellular 
component, D) volume fraction map of the extracellular-extravascular space (EES), 
E) cell radius index map F) cellularity map derived from fIC and R, G) volume fraction 
map of the vascular space, H) kurtosis diffusivity map, I) kurtosis map.  The 
cellularity map clearly distinguishes the tumour from the benign region unlike the rest 
parametric maps. 
Figure 8 Colour-coded per patient scatter plots of voxel by voxel fitting values of the 
ADC d, Dk, K and fIC, R, fEES, fVASC, for the tumour ROIs showing the least-squares 
line and the correlation coefficients for each plot.  For the ADC d and Dk we observe 
strong negative correlation with fIC, and moderate positive correlations with fEES and 
fVASC. The kurtosis K shows strong positive correlation with fIC and moderate negative 
correlation with fEES. 
Figure	  1	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